Avacta Group’s (LSE:AVCT) therapeutics division has released new preclinical data indicating that its pre|CISION platform candidate FAP-Exd (AVA6103) may deliver cancer treatments with greater selectivity and effectiveness than Enhertu, a leading antibody-drug conjugate (ADC). The company used an AI-generated synthetic comparator model based on publicly available AstraZeneca data to evaluate drug delivery performance in FAP-high animal models, comparing two closely related exatecan-family payloads.
According to the analysis, AVA6103 demonstrated faster tumour penetration and achieved peak drug concentrations in tumour tissue more than ten times higher than those observed with Enhertu’s T-Dxd payload. The study also reported a tumour selectivity index nearly three times greater, supporting deeper and more sustained responses in preclinical testing. Avacta plans to initiate a Phase 1 clinical trial for AVA6103 in the first quarter of 2026 and intends to present the findings at upcoming scientific conferences, which could strengthen its positioning within the competitive oncology drug delivery market and attract further investor and partner interest.
Despite scientific progress, the company’s outlook remains constrained by weak financial fundamentals, including ongoing losses and limited commercial partnerships. Technical indicators also point to bearish momentum, while valuation remains difficult to support given negative earnings and the absence of dividend income.
More about Avacta Group plc
Avacta Therapeutics, a division of Avacta Group plc, is a clinical-stage biopharmaceutical business focused on improving the delivery of highly potent cancer therapies. Its proprietary pre|CISION platform uses a fibroblast activation protein (FAP)-targeted peptide system designed to release cytotoxic drugs selectively within solid tumours, aiming to enhance treatment efficacy while reducing toxicity to healthy tissue.
Leave a Reply